Status:
COMPLETED
Valproate in Late Life Schizophrenia
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborating Sponsors:
Abbott
Conditions:
Schizophrenia
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this research study is to analyze the effectiveness and tolerability of a medication, valproate ( Depakote and Depakote ER), in individuals age 50 years and older who have schizophrenia...
Detailed Description
It is known that up to 30% of individuals with schizophrenia continue to have symptoms even when treated with current FDA-approved medications intended to treat their schizophrenia. Anticonvulsant med...
Eligibility Criteria
Inclusion
- Must have a diagnosis of schizophrenia as confirmed by the MINI
- Must be on antipsychotic medication
- Must be age 50 year or older
- Must be capable of providing written informed consent for study participation. In situations where individuals have guardians of person, guardian and subject must both provide written consent; and
- Must live in the Northeast Ohio area.
Exclusion
- A primary psychiatric DSM Axis I diagnosis other than schizophrenia
- Actively abusing substances; or
- Medically unstable.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00194025
Start Date
November 1 2004
End Date
November 1 2006
Last Update
January 6 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106